Key stats
About VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD
Home page
Inception date
Sep 2, 2022
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
VanEck Asset Management BV
ISIN
IE000B9PQW54
The Funds investment objective is to replicate the price and the performance, before fees and expenses, of an index that provides exposure to the performance of a representative portfolio of companies involved in the genomic healthcare and electronic healthcare industries
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Health Services
Technology Services
Stocks99.91%
Health Technology59.42%
Health Services17.42%
Technology Services17.26%
Distribution Services4.16%
Retail Trade0.96%
Electronic Technology0.44%
Commercial Services0.25%
Bonds, Cash & Other0.09%
Cash0.09%
Stock breakdown by region
North America74.50%
Europe11.08%
Asia10.13%
Oceania4.29%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
CURE invests in stocks. The fund's major sectors are Health Technology, with 59.42% stocks, and Health Services, with 17.42% of the basket. The assets are mostly located in the North America region.
CURE top holdings are Vertex Pharmaceuticals Incorporated and Regeneron Pharmaceuticals, Inc., occupying 8.12% and 8.05% of the portfolio correspondingly.
CURE assets under management is 7.15 M USD. It's risen 27.31% over the last month.
CURE fund flows account for −182.16 K USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, CURE doesn't pay dividends to its holders.
CURE shares are issued by VanEck ETP AG under the brand VanEck. The ETF was launched on Sep 2, 2022, and its management style is Passive.
CURE expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
CURE follows the MVIS Global Future Healthcare ESG Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
CURE invests in stocks.
CURE price has risen by 2.11% over the last month, and its yearly performance shows a 6.28% increase. See more dynamics on CURE price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 3.00% over the last month, showed a 6.96% increase in three-month performance and has increased by 7.09% in a year.
NAV returns, another gauge of an ETF dynamics, have risen by 3.00% over the last month, showed a 6.96% increase in three-month performance and has increased by 7.09% in a year.
CURE trades at a premium (1.01%) meaning the ETF is trading at a higher price than the calculated NAV.